Zymeworks Stock Price, News & Analysis (NYSE:ZYME)

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last twelve months. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ZYME shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZYME, but not buy additional shares or sell existing shares.
View ZYME analyst ratings or view top-rated stocks.

7 equities research analysts have issued twelve-month price targets for Zymeworks' shares. Their ZYME share price targets range from $8.00 to $19.00. On average, they expect the company's stock price to reach $12.44 in the next year. This suggests a possible upside of 36.8% from the stock's current price.
View analysts price targets for ZYME or view top-rated stocks among Wall Street analysts.

Zymeworks' stock was trading at $7.86 at the beginning of the year. Since then, ZYME shares have increased by 15.8% and is now trading at $9.10.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024.
View our ZYME earnings forecast.

Zymeworks Inc. (NYSE:ZYME) posted its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.14. The business had revenue of $16.51 million for the quarter, compared to analyst estimates of $10.17 million. Zymeworks had a net margin of 44.47% and a trailing twelve-month return on equity of 44.62%.

Invesco Russell 2000 Dynamic Multifactor ETF holds 148,747 shares of ZYME stock, representing 0.32% of its portfolio.

9 employees have rated Zymeworks Chief Executive Officer Ali Tehrani on Glassdoor.com. Ali Tehrani has an approval rating of 100% among the company's employees. This puts Ali Tehrani in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Zymeworks to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Zymeworks investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Just Energy Group (JE), NVIDIA (NVDA), Just Energy Group (JE), PayPal (PYPL), Alibaba Group (BABA), Cronos Group (CRON), CRISPR Therapeutics (CRSP) and Tesla (TSLA).

(ZYME) raised $65 million in an initial public offering (IPO) on Friday, April 28th 2017. The company issued 4,500,000 shares at a price of $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager.

Zymeworks' stock is owned by a number of retail and institutional investors. Top institutional investors include Morgan Stanley (6.41%), Rubric Capital Management LP (3.79%), Rubric Capital Management LP (3.79%), Acadian Asset Management LLC (1.18%), AQR Capital Management LLC (1.14%) and Jupiter Asset Management Ltd. (0.70%). Insiders that own company stock include Ali Tehrani, Christopher Astle, Ecor1 Capital, Llc, James Priour, Kathryn O'driscoll, Neil A Klompas and Neil Josephson.
View institutional ownership trends.

Shares of ZYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.